(7 Jul 2026) Clarivate has announced that it has entered into a definitive agreement to sell its Life Sciences & Healthcare (LS&H) business to healthcare-focused investment firm Altaris for $600 million.
The transaction marks a significant strategic shift for Clarivate, leaving the company focused on its Academia & Government (A&G) and Intellectual Property (IP) businesses. Following completion of the deal, Clarivate said it will operate as a subscription-first provider of intelligence solutions, workflow software and technology-enabled services across those two segments.
According to the company, the A&G and IP divisions benefit from shared technology platforms and content assets, while serving customers through research, education, library and intellectual property solutions.
The LS&H business provides data, analytics and expertise supporting pharmaceutical and medical device companies throughout the drug and device lifecycle, from research and development through to commercialisation and market access.
The press release in full is here.
